Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27029922 | 0.89 | HCRTR1 (0.71) | HCRTR1HCRTR2 | |
| SCHEMBL11909712 | 0.86 | HCRTR1 (0.67) | HCRTR1HCRTR2 | |
| SCHEMBL1671043 | 0.85 | HCRTR1 (0.66) | HCRTR1HCRTR2 | |
| SCHEMBL29713616 | 0.85 | HCRTR1 (0.66) | HCRTR1HCRTR2 | |
| SCHEMBL30443074 | 0.85 | HCRTR1 (0.66) | HCRTR1HCRTR2 | |
| SCHEMBL27029982 | 0.85 | HCRTR1 (0.66) | HCRTR1HCRTR2 | |
| SCHEMBL1671087 | 0.84 | HCRTR1 (0.63) | HCRTR1HCRTR2 | |
| SCHEMBL27056184 | 0.84 | HCRTR1 (0.63) | HCRTR1HCRTR2 | |
| SCHEMBL30443501 | 0.84 | HCRTR1 (0.63) | HCRTR1HCRTR2 | |
| Seltorexant SCHEMBL19341242 | 0.82 | HCRTR1 (1.00) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258790-A1 | Methods Of Treating Depression Using Orexin-2 Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258790-A1 | Methods Of Treating Depression Using Orexin-2 Receptor Antagonists | HCRTR2, HCRTR1, CRHR2 | HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.